你沒看懂. 沒人質疑俄國疫苗的有效率. 只是回答你的高低問題. Novavax對未變異的病毒有效率是95.6%,相當高.對有變異的英國病毒有效率是89.3%,很不錯. Novavax reported 89.3% efficacy. But here's one important factor to keep in mind: Novavax's phase 3 trial took place in the United Kingdom -- home of the U.K. strain. And the U.K. strain has become more and more prevalent both there and elsewhere. Moderna and Pfizer generated their trial data before the newer variants of concern had gained ground. Their vaccines were primarily fighting the virus they were designed to fight: the original strain of SARS-CoV-2. Novavax's vaccine -- like those of Moderna and Pfizer -- also was designed to combat the first version of the novel coronavirus; it's clear that efficacy will be higher when faced only with that version. In fact, Novavax calculated its candidate's efficacy against the earlier coronavirus at 95.6%.
|